Inmune Bio, Inc. 8-K

What Happened

• On June 2, 2026, Inmune Bio, Inc. (INMB) announced results from exploratory χ-separation (chi-separation) MRI imaging analyses conducted as part of the MINDFuL Phase 2 clinical trial of XPro™ (XPro1595). The analyses cover patients with early Alzheimer’s disease, including mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia. The company filed a Form 8-K reporting this update and attached the press release as Exhibit 99.1.

Key Details

• Date filed: June 2, 2026 (Form 8-K, Item 8.01 Other Events).
• Program: MINDFuL Phase 2 clinical trial of XPro™ (XPro1595).
• Analysis: Exploratory χ-separation (chi-separation) MRI imaging analyses.
• Patient population: Early Alzheimer’s disease — MCI and mild AD dementia.
• Press release attached as Exhibit 99.1 to the Form 8-K.

Why It Matters

• Imaging biomarker analyses like χ-separation MRI are part of clinical data generation that can help characterize the biological effects of XPro in early Alzheimer’s patients. For investors, this update signals progress in Inmune Bio’s Phase 2 development program and provides more detailed clinical data for the company’s therapeutic candidate. The company’s formal disclosure via an 8-K ensures the information is part of the public record.